VCNX (Vaccinex) Total Liabilities: $5.08 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCNX Vaccinex Inc VCNX
50 GF Score
Price $1.18
View Full Analysis

What is Vaccinex Total Liabilities?

Vaccinex VCNX 50 Total Liabilities is $5.08 Mil as of Dec. 2024. GuruFocus rates VCNX with a GF Score™ of 50/100.

Vaccinex's Total Liabilities for the quarter that ended in Dec. 2024 was $5.08 Mil.

Vaccinex's quarterly Total Liabilities increased from Jun. 2024 ($5.23 Mil) to Sep. 2024 ($6.18 Mil) but then declined from Sep. 2024 ($6.18 Mil) to Dec. 2024 ($5.08 Mil).

Vaccinex's annual Total Liabilities increased from Dec. 2022 ($2.78 Mil) to Dec. 2023 ($5.94 Mil) but then declined from Dec. 2023 ($5.94 Mil) to Dec. 2024 ($5.08 Mil).


Vaccinex Total Liabilities Historical Data

* Premium members only.

The historical data trend for Vaccinex's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaccinex Total Liabilities Chart

Vaccinex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 14.31 2.43 2.78 5.94 5.08

Vaccinex Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.94 4.71 5.23 6.18 5.08
VCNX
50GF Score
Vaccinex Inc VCNX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaccinex Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vaccinex's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=2.596--2.488
=5.08

Vaccinex's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=2.596--2.488
=5.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $5.08 Mil mean?
Vaccinex (VCNX) has a Total Liabilities of $5.08 Mil as of Dec. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vaccinex and its competitors.
Is Vaccinex's Total Liabilities too high?
Vaccinex's current Total Liabilities is $5.08 Mil. Overall, Vaccinex has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaccinex's Total Liabilities compare to SXTP and PHGE?
Vaccinex's Total Liabilities of $5.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vaccinex and its competitors. Vaccinex's current Total Liabilities is $5.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaccinex stock overvalued right now?
Vaccinex (VCNX) has a current Total Liabilities of $5.08 Mil. The current Total Liabilities is $5.08 Mil. Vaccinex's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Vaccinex (VCNX), the current Total Liabilities is $5.08 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaccinex Business Description

Address 1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is a clinical stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company operates and manages its business as one operating and reportable segment, which is the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. The firm has also developed a proprietary drug discovery platform, ActivMAb.
50GF Score

Get the complete analysis for VCNX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price